WO2021128659A1 - 特异性引物探针组合及其适于血液直接扩增结合荧光pcr法检测叶酸代谢能力基因的应用 - Google Patents

特异性引物探针组合及其适于血液直接扩增结合荧光pcr法检测叶酸代谢能力基因的应用 Download PDF

Info

Publication number
WO2021128659A1
WO2021128659A1 PCT/CN2020/084706 CN2020084706W WO2021128659A1 WO 2021128659 A1 WO2021128659 A1 WO 2021128659A1 CN 2020084706 W CN2020084706 W CN 2020084706W WO 2021128659 A1 WO2021128659 A1 WO 2021128659A1
Authority
WO
WIPO (PCT)
Prior art keywords
amplification
fluorescent
primer
pcr reaction
specific primer
Prior art date
Application number
PCT/CN2020/084706
Other languages
English (en)
French (fr)
Inventor
肖磊
李刚
颜桦
郝婷
Original Assignee
陕西佰美基因股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陕西佰美基因股份有限公司 filed Critical 陕西佰美基因股份有限公司
Publication of WO2021128659A1 publication Critical patent/WO2021128659A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • This application belongs to the field of genetic diagnosis, and relates to a detection method for folic acid metabolism capacity genotyping (MTHFR gene C677T locus polymorphism).
  • MTHFR Methylene tetrahydmfolate reductase
  • C677T site is the most common polymorphism of MTHFR gene. This mutation can cause differences in enzyme activity and affect folate metabolism in the body. Studies have shown that C677T polymorphism is significantly related to cardiovascular and cerebrovascular diseases caused by high homocysteine, habitual abortion in pregnant women, fetal birth defects such as neural tube defects, and congenital heart disease.
  • DNA extraction is an indispensable link.
  • the experimental process of DNA-based PCR method takes a long time and is easy to cause pollution. In addition to the increase of experimental steps, it also increases the cost.
  • Sanger sequencing is the gold standard for genetic testing, it is costly and insufficient in throughput, making it unsuitable for large-scale clinical analysis.
  • the purpose of this application is to target the C677T polymorphism of the MTHFR gene, and solve the problems that the existing detection method requires blood DNA extraction, the process is time-consuming, easy to cause pollution, and the cost is high.
  • the design idea of this application is: direct blood amplification combined with the fluorescent PCR method, the core of which is to use a nucleic acid release agent to release DNA from the nucleated cells of anticoagulated whole blood, and add the nucleic acid release agent MIX to a reaction system to expand Enzyme increase, and design specific ARMS primers and modified probes; select a suitable amplification program, collect fluorescence signals, and obtain corresponding genotypes based on the fluorescence signal graph.
  • a specific primer-probe combination suitable for direct blood amplification combined with a fluorescent PCR method is targeted at the folate metabolism gene, specifically the C677T site of the MTHFR gene;
  • the specific primer-probe combination includes: target gene ARMS primers, universal primers and fluorescent probes;
  • the target gene ARMS primers are divided into C genotype specific primers and T genotype specific primers;
  • C genotype specific primer AGAAGGTGTCTGCGGGATC;
  • T genotype specific primer AGAAGGTGTCTGCGGGATT;
  • Fluorescent probe 5'-HEX-TTCTTCCGCTTTGTGAAGGCATGC-BHQ1-3';
  • HEX is a fluorescence modification group
  • BHQ1 is a fluorescence quenching group
  • the direct blood amplification combined with fluorescent PCR method is for anticoagulated whole blood samples, adding a nucleic acid release agent, an amplification enzyme, and the specific primer probe combination to the reaction system to perform a fluorescent PCR program to obtain the corresponding genotype.
  • the above-mentioned specific primer probe combination is used in preparing a kit for detecting the polymorphism of the C677T site of the MTHFR gene.
  • kits for detecting the polymorphism of the C677T site of the MTHFR gene comprising: the above-mentioned specific primer probe combination, the primer probe combination of the internal reference gene, nucleic acid release agent, amplification enzyme and ultrapure water
  • the fluorescent probe in the primer probe combination of the internal reference gene and the fluorescent probe in the specific primer probe combination adopt different fluorescent modification groups (FAM modification).
  • sequence information of the primer probe combination of the internal reference gene is as follows:
  • Fluorescent probe 5'-FAM–AGGAGTATGACGAGTCCGGCCCC-BHQ1--3'.
  • a blood direct amplification combined with fluorescent PCR detection method for the C677T polymorphism of the MTHFR gene is used for non-disease diagnosis purposes, including the following steps:
  • the first set of PCR reaction systems includes:
  • 677C specific primer AGAAGGTGTCTGCGGGATC;
  • 677 fluorescent probe 5'-HEX-TTCTTCCGCTTTGTGAAGGCATGC-BHQ1-3';
  • ACTB upstream primer CAGCAGATGTGGATCAGCAAG
  • ACTB downstream primer GCATTTGCGGTGGACGAT;
  • ACTB fluorescent probe 5'-FAM–AGGAGTATGACGAGTCCGGCCCC-BHQ1--3';
  • nucleic acid release agents As well as nucleic acid release agents, amplification enzymes and ultrapure water;
  • 677T specific primer AGAAGGTGTCTGCGGGATT, others are the same;
  • step (3) Add the anticoagulated whole blood samples obtained in step (1) into the two sets of PCR reaction systems respectively, and run the real-time fluorescent PCR amplification program;
  • the sample shows normal amplification in the FAM channel and HEX channel in the first set of PCR reaction system and the second set of PCR reaction system, and the absolute value of the difference between the Ct values of the two reactions is ⁇ 3, then the sample The genotype is CT heterozygous;
  • step (3) runs a real-time fluorescent PCR amplification program, specifically as follows: 95°C pre-denaturation for 5 minutes; 95°C denaturation for 30 seconds, 60°C annealing for 30 seconds, 72°C extension for 60 seconds, a total of 40 cycles; 72 Extend for 1 minute at °C; cool the instrument to 4 °C.
  • the intelligent detection device supports the above-mentioned direct blood amplification combined with fluorescent PCR detection method Execution (such as configuring control algorithms, input and output parameters, etc.).
  • This new method for detecting the C677T genotype of MTHFR has the advantages of quickness, simplicity, economy and high throughput. Compared with the traditional method, this method does not have the blood DNA extraction link, and has a significant improvement in time and cost.
  • the direct blood amplification combined with the fluorescent PCR method of the present invention requires less sample volume (only 10 ul of blood is required), saves the extraction and purification steps of nucleic acid substances, is simple, fast, accurate, and saves costs.
  • Figure 1 is a simplified flow chart of the existing Sanger method.
  • Figure 2 is a schematic flow chart of the existing DNA-based fluorescent probe method.
  • Figure 3 is a schematic flow diagram of the blood direct amplification PCR method of the present invention.
  • Figure 4 is a graph showing the results of a heterozygous CT genotyping experiment according to an embodiment of the present invention.
  • Figure 5 is a graph showing the results of a homozygous CC genotype experiment according to an embodiment of the present invention.
  • Figure 6 is a graph showing the results of a homozygous TT genotype experiment according to an embodiment of the present invention.
  • Fig. 7 is a diagram showing the overall experimental results of 30 samples completed by using the blood direct expansion fluorescent PCR method of the present invention.
  • Primer design According to the nucleic acid sequence information near the C677T site of the MTHFR gene, design ARMS primers and detection probes, and design primers and probes for internal reference genes. The primers are entrusted to Shanghai Shenggong Biosynthesis.
  • T genotype specific primer AGAAGGTGTCTGCGGGATT
  • Fluorescent probe TCTTCCGCTTTGTGAAGGCATGC 5'HEX 3'BHQ1
  • Fluorescent probe AGGAGTATGACGAGTCCGGCCCC 5'FAM 3'BHQ1
  • Sample preparation choose EDTA anticoagulated whole blood, which needs to be mixed before use, so that the white blood cells are evenly distributed.
  • Nucleic acid release agent MIX2 ⁇ Superstart Direct Premix (Probe qPCR) (Probe Biotech)
  • the overall experiment of the detection method takes about 2 to 3 hours.
  • PCR reaction MIX Prepares PCR reaction MIX. Add PCR enzyme MIX, primers and water to the PCR reaction tube according to the reaction system, mix thoroughly, add 1ul DNA sample to the corresponding MIX tube, and run the program on the ABI Veriti 96-well PCR machine: 95°C Pre-denaturation for 5 minutes; denaturation at 95°C for 30 seconds, annealing at 60°C for 30 seconds, extension at 72°C for 60 seconds (collecting signals), 40 cycles; extension at 72°C for 1 minute; cooling the instrument to 4°C (about 2.5 hours).
  • the overall experiment of the detection method takes about 9-10 hours.
  • PCR reaction MIX Prepares PCR reaction MIX. Add fluorescent PCR enzyme MIX, primers, probes and water to the PCR reaction tube, mix well, add 1ul DNA sample to the corresponding MIX tube, and run the program in ABI Viia7: 95°C pre-denaturation 5 Minutes; denaturation for 30 seconds, annealing at 60°C for 30 seconds, extension at 72°C for 60 seconds (collecting signals), 40 cycles; extension at 72°C for 1 minute; cooling the instrument to 4°C (about 2.5 hours)
  • the overall experiment of the detection method takes about 5-6 hours.
  • the blood direct amplification fluorescence PCR method of this embodiment compares the detection results with the other two detection methods, and the advantages are significant:
  • the blood direct amplification fluorescence PCR method has completed the comparison of 100 samples from the fluorescence PCR method and 30 samples sequenced by Sanger, and the results are completely consistent.
  • Figure 7 is a diagram showing the overall experimental results of 30 samples completed by the blood direct amplification fluorescent PCR method.
  • Time-saving Comparison of the three. In terms of time, the blood direct amplification PCR method takes about 3 hours to complete a single sample. Compared with the 5h of the fluorescence method, the 9h of Sanger sequencing is shorter, and the efficiency is greatly improved.
  • the blood direct amplification fluorescent PCR method eliminates the DNA extraction step, and at least saves the cost of the DNA extraction kit (Tiangen's blood/cell/tissue genomic DNA extraction kit is about 8 Yuan/per sample), and Sanger sequencing is more expensive.
  • the experimental process is streamlined while also saving manpower consumption.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明提供了一种特异性引物探针组合及其适于血液直接扩增结合荧光PCR法检测叶酸代谢能力基因的应用。针对MTHFR基因C677T位点，该特异性引物探针组合包括：目的基因ARMS引物、通用引物及荧光探针；具体有：C基因型特异性引物：AGAAGGTGTCTGCGGGATC；T基因型特异性引物：AGAAGGTGTCTGCGGGATT；通用引物：GGGACGATGGGGCAAGTG；荧光探针：5'-HEX-TTCTTCCGCTTTGTGAAGGCATGC-BHQ1-3'。

Description

特异性引物探针组合及其适于血液直接扩增结合荧光PCR法检测叶酸代谢能力基因的应用 技术领域
本申请属于基因诊断领域，涉及一种针对叶酸代谢能力基因分型(MTHFR基因C677T位点多态性)的检测方法。
背景技术
亚甲基四氢叶酸还原酶(methylene tetrahydmfolatereductase,MTHFR)是人体叶酸代谢的关键酶，其中C677T位点突变是MTHFR基因最常见的多态性，该突变会导致酶活性差异，影响机体叶酸代谢。研究表明，C677T多态性与高同型半胱氨酸所致的心脑血管疾病、妊娠期妇女习惯性流产、胎儿出生缺陷如神经管缺陷、先天性心脏病等明显相关。我国《高血压合理用药指南》(第二版)和《围受孕期增补叶酸预防神经管缺陷指南(2017)》均明确指出应基于MTHFR基因C677T检测结果进行个体化干预，合理补充叶酸，防止高血压并发症和出生缺陷。
而针对MTHFR基因C677T位点多态性的检测，目前市场上采用最多的方法大多是在抗凝全血的基础上提取、纯化出核酸物质(DNA)，运用Sanger测序、荧光法或TaqMan探针实时PCR等方法进行基因分型，通过检测基因型对相应的疾病进行用药指导和早期预防。但以上方法都存在自身的局限性，DNA提取是必不可少的环节，但是基于DNA的PCR方法实验流程耗时较长，易造成污染，在增加了实验步骤的基础上还增加了成本。另外，Sanger测序虽然 是基因检测金标准，但成本高昂，通量不足，不适于临床大规模分析。
发明内容
本申请的目的是针对MTHFR基因C677T位点多态性，解决现有检测方法需要进行血液DNA提取环节、流程耗时较长、易造成污染且成本较高等问题。
本申请的设计思路是：血液直接扩增结合荧光PCR方法，其核心是利用核酸释放剂让DNA从抗凝全血的有核细胞中释放出来，在一个反应体系中加入核酸释放剂MIX，扩增酶、并设计特定的ARMS引物、修饰探针；选择合适的扩增程序，采集荧光信号，根据荧光信号图得出相应基因型。
本申请的具体解决方案如下：
第一方面，一种适用于血液直接扩增结合荧光PCR方法的特异性引物探针组合，其针对叶酸代谢能力基因，具体是MTHFR基因C677T位点；该特异性引物探针组合包括：目的基因ARMS引物、通用引物及荧光探针；所述目的基因ARMS引物分为C基因型特异性引物和T基因型特异性引物；
C基因型特异性引物：AGAAGGTGTCTGCGGGATC；
T基因型特异性引物：AGAAGGTGTCTGCGGGATT；
通用引物：GGGACGATGGGGCAAGTG；
荧光探针：5'-HEX-TTCTTCCGCTTTGTGAAGGCATGC-BHQ1-3'；
其中，HEX为荧光修饰基团，BHQ1为荧光淬灭基团；
所述血液直接扩增结合荧光PCR方法是针对抗凝全血样本，在反应体系中加入核酸释放剂、扩增酶、以及所述特异性引物探针组合进行荧光PCR程序得出相应基因型。
第二方面，上述的特异性引物探针组合在制备针对MTHFR基因C677T位点多态性检测的试剂盒方面的用途。
第三方面，一种针对MTHFR基因C677T位点多态性检测的试剂盒，包括：上述的特异性引物探针组合、内参基因的引物探针组合、核酸释放剂、扩增酶和超纯水，所述内参基因的引物探针组合中的荧光探针与所述特异性引物探针组合中的荧光探针采用不同的荧光修饰基团(FAM修饰)。
进一步优选的，所述内参基因的引物探针组合的序列信息如下：
上游引物：CAGCAGATGTGGATCAGCAAG
下游引物：GCATTTGCGGTGGACGAT
荧光探针：5'-FAM–AGGAGTATGACGAGTCCGGCCCC-BHQ1--3'。
第四方面，一种针对MTHFR基因C677T位点多态性的血液直接扩增结合荧光PCR检测方法，用于非疾病诊断目的，包括以下步骤：
(1)获取待测抗凝全血样本，并用超纯水稀释；
(2)配置两组PCR反应体系，其中：第一组PCR反应体系包括：
677C特异性引物：AGAAGGTGTCTGCGGGATC；
677通用引物：GGGACGATGGGGCAAGTG；
677荧光探针：5'-HEX-TTCTTCCGCTTTGTGAAGGCATGC-BHQ1-3'；
ACTB上游引物：CAGCAGATGTGGATCAGCAAG；
ACTB下游引物：GCATTTGCGGTGGACGAT；
ACTB荧光探针：5'-FAM–AGGAGTATGACGAGTCCGGCCCC-BHQ1--3'；
以及核酸释放剂、扩增酶和超纯水；
第二组PCR反应体系与第一组PCR反应体系的区别仅在于将677C特异性引物替换为：
677T特异性引物：AGAAGGTGTCTGCGGGATT，其他均相同；
两组PCR反应体系分别充分混匀；
(3)在两组PCR反应体系中分别加入步骤(1)得到的抗凝全血样本，运行实时荧光PCR扩增程序；
(4)根据两组PCR反应体系的扩增情况判断样本基因型；判读标准如下：
a)若该样本在第一组PCR反应体系和第二组PCR反应体系中的FAM通道、HEX通道均表现出正常扩增，且两个反应Ct的值差的绝对值<3，则该样本为基因型为CT杂合型；
b)若该样本在第二组PCR反应体系中的FAM通道呈现正常扩增，而在第一组PCR反应体系中的HEX通道呈现正常扩增,则表 明该样本基因型为CC纯合型；
c)若该样本在第一组PCR反应体系中的FAM通道呈现正常扩增，而在第二组PCR反应体系中的HEX通道呈现正常扩增,则表明该样本基因型为TT纯合型。
进一步优选地，步骤(3)运行实时荧光PCR扩增程序，具体如下：95℃预变性5分钟；95℃变性30秒，60℃退火30秒，72℃延伸60秒，共40个循环；72℃延伸1分钟；仪器降温到4℃。
第五方面，上述的特异性引物探针组合在构建针对MTHFR基因C677T位点多态性检测的智能检测设备方面的用途，所述智能检测设备支持上述的血液直接扩增结合荧光PCR检测方法的执行(例如配置控制算法、输入输出参数等)。
该检测MTHFR的C677T基因型的新方法，具有快速简便，经济和高通量的优点。相对与传统方法，此方法少了血液DNA的提取环节，从时间和成本上都有了显著的改善。
本发明的血液直接扩增结合荧光PCR方法，样本量需求少(仅仅需要10ul血液)，节省了核酸物质的提取和纯化步骤，简便、快捷、准确、节省成本。
目前POCT市场在全球范围内稳定发展，该方法具有转化的优势，可以通过指尖采血，仅用一滴血液就可实现准确的检测，临床应用时即减少了患者因静脉采血造成的恐慌，也降低了医疗器械资源的浪费。
附图说明
图1为现有的Sanger法的流程简图。
图2为现有的基于DNA的荧光探针法的流程简图。
图3为本发明的血液直扩PCR法的流程简图。
图4为本发明一个实施例的杂合CT基因型实验结果图。
图5为本发明一个实施例的纯合CC基因型实验结果图。
图6为本发明一个实施例的纯合TT基因型实验结果图。
图7为采用本发明的血液直扩荧光PCR法完成30例样本整体实验结果图。
具体实施方式
以下通过一个实施例结合附图，详细介绍本发明及其与现有技术的实施效果对比。
本发明的一个实施例：
一、前期准备：
引物设计：根据MTHFR基因C677T位点附近的核酸序列信息，设计ARMS引物及检测探针，同时设计内参基因引物及探针，引物委托上海生工生物合成。
位点序列信息：
>gnl|dbSNP|rs1801133|allelePos＝501|totalLen＝1001|taxid＝9606|snpclass＝1|alleles＝'C/T'|mol＝Genomic|build＝151
Figure PCTCN2020084706-appb-000001
Figure PCTCN2020084706-appb-000002
目的基因ARMS引物序列信息：
C基因型特异性引物：AGAAGGTGTCTGCGGGATC
T基因型特异性引物：AGAAGGTGTCTGCGGGATT
通用引物：GGGACGATGGGGCAAGTG
荧光探针：TTCTTCCGCTTTGTGAAGGCATGC 5'HEX 3'BHQ1
内参基因引物序列信息：
上游引物：CAGCAGATGTGGATCAGCAAG
下游引物：GCATTTGCGGTGGACGAT
荧光探针：AGGAGTATGACGAGTCCGGCCCC 5'FAM 3'BHQ1
样本准备：选取EDTA抗凝全血，需要在使用前混匀，让其中的白细胞均匀分布。
试剂准备：
引物(生工生物合成)
核酸释放剂MIX2×Superstart Direct Premix(Probe qPCR)(宝锐生物)
扩增酶FastStart Essential DNA Probes Master(Roche)
超纯水。
二、血液直扩PCR法实验流程(如图3所示)：
1、按4倍比例用超纯水稀释抗凝全血。
2、配制PCR反应MIX(两孔/样本)，在PCR反应管中分别加入核酸释放剂MIX、引物、探针和水，充分混匀，MIX体系如表1(以单管总体积20ul计)。
表1血液直扩PCR反应体系
Figure PCTCN2020084706-appb-000003
在对应两MIX管中分别加入1ul稀释好的全血样本，在ABI Viia7运行程序：95℃预变性5分钟；95℃变性30秒，60℃退火30秒，72℃延伸60秒(收集信号)，40个循环；72℃延伸1分钟；仪 器降温到4℃(约1.5小时)。
3、结果分析：
结果判读标准：
a)若该样本在反应体系1和反应体系2中的FAM通道、HEX通道均表现出正常扩增，且两个反应Ct的值差的绝对值<3，则该样本为基因型为CT杂合型；
b)若该样本在反应体系2中的FAM通道呈现正常扩增，而在反应体系1中的HEX通道呈现正常扩增,则表明该样本基因型为CC纯合型；
c)若该样本在反应体系1中的FAM通道呈现正常扩增，而在反应体系2中的HEX通道呈现正常扩增,则表明该样本基因型为TT纯合型；
根据标准对结果进行判读，给出最终的基因型，如图4、图5、图6所示。
该检测方法整体实验约耗时2～3h。
以下简要介绍Sanger法和基于DNA的荧光探针的实时PCR法。
Sanger测序(如图1所示)：
1、准备EDTA抗凝全血(至少500ul)。
2、从抗凝血中提取全基因组DNA(普通试剂盒提取约需要2小时)。
3、DNA质检，合格后继续后续实验步骤。
4、配制PCR反应MIX在PCR反应管中按反应体系分别加入 PCR酶MIX、引物和水，充分混匀，在对应MIX管加入1ul的DNA样本，在ABI Veriti 96孔PCR仪运行程序：95℃预变性5分钟；95℃变性30秒，60℃退火30秒，72℃延伸60秒(收集信号)，40个循环；72℃延伸1分钟；仪器降温到4℃(约2.5小时)。
5、进行上一步PCR产物的纯化，测序(3500仪器整个流程约需要5h)。
6、结果分析：根据结果判读标准，对结果进行判读，给出最终的基因型。
该检测方法整体实验约耗时9～10小时。
基于DNA的荧光探针的实时PCR法(如图2所示)：
1、准备EDTA抗凝全血(至少500ul)。
2、从抗凝血中提取全基因组DNA(普通试剂盒提取约需要2小时)。
3、DNA质检，合格后继续后续实验步骤。
4、配制PCR反应MIX在PCR反应管中分别加入荧光PCR酶MIX、引物、探针和水，充分混匀，在对应MIX管加入1ul的DNA样本，在ABI Viia7运行程序：95℃预变性5分钟；变性30秒，60℃退火30秒，72℃延伸60秒(收集信号)，40个循环；72℃延伸1分钟；仪器降温到4℃(约2.5小时)
5、结果分析：根据结果判读标准，对结果进行判读，给出最终的基因型。
该检测方法整体实验约耗时5～6小时。
经多例样本实验，本实施例的血液直扩荧光PCR法与另两种检测方法检测结果比对，优势显著：
准确：血液直扩荧光PCR法完成与荧光PCR法的100例样本、Sanger测序的30例样本的比对，结果完全一致。图7为采用血液直扩荧光PCR法完成30例样本整体实验结果图。
省时：三者对比在时间上，血液直扩荧光PCR法完成单样本的时间约3小时，相比荧光法的5h，Sanger测序的9h更短，效率得到大大提高。
降低成本：成本上，相比荧光PCR法，血液直扩荧光PCR法省去了提取DNA步骤，至少要节约DNA提取试剂盒的成本(天根的血液/细胞/组织基因组DNA提取试剂盒约8元/每样本)，而Sanger测序的成本更高。另一方面，实验流程精简的同时也节省了人力消耗。

Claims (7)

  1. 一种适用于血液直接扩增结合荧光PCR方法的特异性引物探针组合，其针对叶酸代谢能力基因，具体是MTHFR基因C677T位点；该特异性引物探针组合包括：目的基因ARMS引物、通用引物及荧光探针；所述目的基因ARMS引物分为C基因型特异性引物和T基因型特异性引物；
    C基因型特异性引物：AGAAGGTGTCTGCGGGATC；
    T基因型特异性引物：AGAAGGTGTCTGCGGGATT；
    通用引物：GGGACGATGGGGCAAGTG；
    荧光探针：5'-HEX-TTCTTCCGCTTTGTGAAGGCATGC-BHQ1-3'；
    其中，HEX为荧光修饰基团，BHQ1为荧光淬灭基团；
    所述血液直接扩增结合荧光PCR方法是针对抗凝全血样本，在反应体系中加入核酸释放剂、扩增酶、以及所述特异性引物探针组合进行荧光PCR程序得出相应基因型。
  2. 权利要求1所述的特异性引物探针组合在制备针对MTHFR基因C677T位点多态性检测的试剂盒方面的用途。
  3. 一种针对MTHFR基因C677T位点多态性检测的试剂盒，其特征在于，包括：权利要求1所述的特异性引物探针组合、内参基 因的引物探针组合、核酸释放剂、扩增酶和超纯水，所述内参基因的引物探针组合中的荧光探针与所述特异性引物探针组合中的荧光探针采用不同的荧光修饰基团。
  4. 根据权利要求3所述的试剂盒，其特征在于：所述内参基因的引物探针组合的序列信息如下：
    上游引物：CAGCAGATGTGGATCAGCAAG
    下游引物：GCATTTGCGGTGGACGAT
    荧光探针：5'-FAM–AGGAGTATGACGAGTCCGGCCCC-BHQ1--3'。
  5. 一种针对MTHFR基因C677T位点多态性的血液直接扩增结合荧光PCR检测方法，用于非疾病诊断目的，包括以下步骤：
    (1)获取待测抗凝全血样本，并用超纯水稀释；
    (2)配置两组PCR反应体系，其中：第一组PCR反应体系包括：
    677C特异性引物：AGAAGGTGTCTGCGGGATC；
    677通用引物：GGGACGATGGGGCAAGTG；
    677荧光探针：5'-HEX-TTCTTCCGCTTTGTGAAGGCATGC-BHQ1-3'；
    ACTB上游引物：CAGCAGATGTGGATCAGCAAG；
    ACTB下游引物：GCATTTGCGGTGGACGAT；
    ACTB荧光探针：5'-FAM–AGGAGTATGACGAGTCCGGCCCC- BHQ1--3'；
    以及核酸释放剂、扩增酶和超纯水；
    第二组PCR反应体系与第一组PCR反应体系的区别仅在于将677C特异性引物替换为：
    677T特异性引物：AGAAGGTGTCTGCGGGATT，其他均相同；
    两组PCR反应体系分别充分混匀；
    (3)在两组PCR反应体系中分别加入步骤(1)得到的抗凝全血样本，运行实时荧光PCR扩增程序；
    (4)根据两组PCR反应体系的扩增情况判断样本基因型；判读标准如下：
    a)若该样本在第一组PCR反应体系和第二组PCR反应体系中的FAM通道、HEX通道均表现出正常扩增，且两个反应Ct的值差的绝对值<3，则该样本为基因型为CT杂合型；
    b)若该样本在第二组PCR反应体系中的FAM通道呈现正常扩增，而在第一组PCR反应体系中的HEX通道呈现正常扩增,则表明该样本基因型为CC纯合型；
    c)若该样本在第一组PCR反应体系中的FAM通道呈现正常扩增，而在第二组PCR反应体系中的HEX通道呈现正常扩增,则表明该样本基因型为TT纯合型。
  6. 根据权利要求5所述的血液直接扩增结合荧光PCR检测方法，其特征在于：步骤(3)运行实时荧光PCR扩增程序，具体如下：95℃预变性5分钟；95℃变性30秒，60℃退火30秒，72℃延 伸60秒，共40个循环；72℃延伸1分钟；仪器降温到4℃。
  7. 权利要求1所述的特异性引物探针组合在构建针对MTHFR基因C677T位点多态性检测的智能检测设备方面的用途，所述智能检测设备支持权利要求5所述的血液直接扩增结合荧光PCR检测方法的执行。
PCT/CN2020/084706 2019-12-24 2020-04-14 特异性引物探针组合及其适于血液直接扩增结合荧光pcr法检测叶酸代谢能力基因的应用 WO2021128659A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911341764.6 2019-12-24
CN201911341764.6A CN111020026A (zh) 2019-12-24 2019-12-24 特异性引物探针组合及其适于血液直接扩增结合荧光pcr法检测叶酸代谢能力基因的应用

Publications (1)

Publication Number Publication Date
WO2021128659A1 true WO2021128659A1 (zh) 2021-07-01

Family

ID=70211733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/084706 WO2021128659A1 (zh) 2019-12-24 2020-04-14 特异性引物探针组合及其适于血液直接扩增结合荧光pcr法检测叶酸代谢能力基因的应用

Country Status (2)

Country Link
CN (1) CN111020026A (zh)
WO (1) WO2021128659A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111996244B (zh) * 2020-10-28 2022-05-06 浙江绍兴鼎晶生物医药科技股份有限公司 一种单核苷酸多态性检测用组合物及其应用
CN112538528A (zh) * 2020-12-25 2021-03-23 上海美吉逾华生物医药科技有限公司 一种检测aldh2基因多态性的引物组及试剂盒
CN114107488A (zh) * 2021-12-28 2022-03-01 上海美吉逾华生物医药科技有限公司 一种检测mthfr基因多态性的引物组及试剂盒
CN116179658B (zh) * 2023-03-29 2023-12-26 中国人民解放军军事科学院军事医学研究院 一种荧光引物扩增阻滞突变系统及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134709A1 (en) * 2005-12-14 2007-06-14 Xiping Xu Usages of MTHFR gene polymorphisms in predicting homocysteine level, disease risk, and treatment effects and related methods and kit
CN101613749A (zh) * 2009-08-11 2009-12-30 中国人民解放军第二军医大学 Papolb基因甲基化定量检测方法
CN105256019A (zh) * 2015-10-14 2016-01-20 武汉海吉力生物科技有限公司 Mthfr和mtrr基因多态性检测引物组及试剂盒
CN105624296A (zh) * 2016-01-28 2016-06-01 屈强 基于arms荧光pcr法检测基因多态性的通用型荧光发夹引物
CN110004215A (zh) * 2018-01-04 2019-07-12 江苏正大天创生物工程有限公司 人类mthfr基因多态性检测试剂盒
CN110272987A (zh) * 2019-06-11 2019-09-24 中山大学达安基因股份有限公司 一种mthfr基因c677t位点快速分型检测试剂盒及方法
CN110272988A (zh) * 2019-06-19 2019-09-24 江苏正大天创生物工程有限公司 人类mthfr基因多态性检测试剂盒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101927884B1 (ko) * 2010-09-06 2018-12-14 주식회사 파나진 Ｐｎａ 기반의 실시간 ｐｃｒ 클램핑을 이용한 ｍｔｈｆｒ 유전자의 유전형 분석 방법 및 키트
CN107630073A (zh) * 2017-10-30 2018-01-26 厦门基源医疗科技有限公司 一种叶酸代谢基因多态性位点的基因型检测方法及试剂盒
CN110423801A (zh) * 2019-09-06 2019-11-08 北京协和洛克生物技术有限责任公司 Mthfr和mtrr基因多态性检测引物、探针、试剂盒及应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134709A1 (en) * 2005-12-14 2007-06-14 Xiping Xu Usages of MTHFR gene polymorphisms in predicting homocysteine level, disease risk, and treatment effects and related methods and kit
CN101613749A (zh) * 2009-08-11 2009-12-30 中国人民解放军第二军医大学 Papolb基因甲基化定量检测方法
CN105256019A (zh) * 2015-10-14 2016-01-20 武汉海吉力生物科技有限公司 Mthfr和mtrr基因多态性检测引物组及试剂盒
CN105624296A (zh) * 2016-01-28 2016-06-01 屈强 基于arms荧光pcr法检测基因多态性的通用型荧光发夹引物
CN110004215A (zh) * 2018-01-04 2019-07-12 江苏正大天创生物工程有限公司 人类mthfr基因多态性检测试剂盒
CN110272987A (zh) * 2019-06-11 2019-09-24 中山大学达安基因股份有限公司 一种mthfr基因c677t位点快速分型检测试剂盒及方法
CN110272988A (zh) * 2019-06-19 2019-09-24 江苏正大天创生物工程有限公司 人类mthfr基因多态性检测试剂盒

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAI WEI: "Relationship between MTHFR C677T Gene Polymorphism and Recurrent Spontaneous Abortion Detected by PCR-fluorescence Probe Method", SHULI YIYAOXUE ZAZHI = JOURNAL OF MATHEMATICAL MEDICINE, WUHAN DAXUE YIXUEYUAN, CN, vol. 32, no. 6, 1 January 2019 (2019-01-01), CN, pages 868 - 870, XP055827311, ISSN: 1004-4337, DOI: 10.3969/j.issn.1004-4337.2019.06.035 *
VON AHSEN N ET AL: "A method for homogeneous color-compensated genotyping of factor V (G1691A) and methylenetetrahydrofolate reductase (C677T) mutations using real-time multiplex fluorescence PCR.", CLINICAL BIOCHEMISTRY, ELSEVIER INC, US, CA, vol. 33, no. 7, 1 October 2000 (2000-10-01), US, CA, pages 535 - 539, XP002261668, ISSN: 0009-9120, DOI: 10.1016/S0009-9120(00)00161-2 *

Also Published As

Publication number Publication date
CN111020026A (zh) 2020-04-17

Similar Documents

Publication Publication Date Title
WO2021128659A1 (zh) 特异性引物探针组合及其适于血液直接扩增结合荧光pcr法检测叶酸代谢能力基因的应用
WO2020215652A1 (zh) 基于核酸酶偶联pcr原理富集低丰度dna突变的检测技术体系及应用
CN105695567A (zh) 一种用于检测胎儿染色体非整倍体的试剂盒、引物和探针序列及检测方法
WO2016049878A1 (zh) 一种基于snp分型的亲子鉴定方法及应用
CN111235272B (zh) 一次性检测肺癌多重基因突变的组合物及其应用
CN115786459B (zh) 一种应用于高通量测序检测实体瘤微小残留病的方法
CN109055532B (zh) 胚胎植入前遗传性耳聋基因检测用引物组合物、试剂盒及应用
CN111455044B (zh) 一种用于母羊早期妊娠诊断的外泌体miRNA标志物及其应用
CN109694907B (zh) 一种无创产前筛查三体综合征的试剂盒及其应用
CN109593846A (zh) 检测叶酸代谢能力相关基因的引物、探针及试剂盒
CN106939334B (zh) 一种孕妇血浆中胎儿dna含量的检测方法
CN109182493B (zh) 人16p11.2微缺失综合征检测的引物和试剂盒及其检测方法
CN113136418B (zh) 一种检测y染色体微缺失的引物及探针的组合物、非诊断目的的检测方法及试剂盒
CN109321651A (zh) 一种检测人cyp2d6基因多态性的组合物、试剂盒、样品处理方法和应用
CN110923306A (zh) 基于数字pcr无创产前检测胎儿21-三体综合征的引物、探针、试剂盒及方法
CN112195278A (zh) 一种六项呼吸道病毒核酸检测试剂盒及使用方法
CN115404268B (zh) 一种sry基因检测探针和试剂盒
CN111471761A (zh) 检测cyp21基因突变的引物、试剂盒及其应用
CN110951857B (zh) 基于数字pcr无创产前检测胎儿21、18、13三体综合征的方法及试剂盒
CN114214416B (zh) 与宫颈癌前病变发生相关联的生物标志物及其应用
CN113186277B (zh) 一种先天性巨结肠的标志物及其应用
CN104232754A (zh) 一种检测11β-羟化酶缺乏症相关基因突变的试剂盒
CN104388552A (zh) 一种检测拟盐皮质激素增多症相关基因突变的试剂盒
CN112899358A (zh) 一种无创产前胎儿染色体非整倍体的检测方法及其试剂盒
WO2021082358A1 (zh) 一种检测HTR2A基因rs6313位点的TaqMan探针实时荧光PCR方法及其引物探针组合

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20907070

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20907070

Country of ref document: EP

Kind code of ref document: A1